Non-small cell lung cancer-small cell lung cancer transformation as mechanism of resistance to tyrosine kinase inhibitors in lung cancer

Mutated or rearranged driver kinases in non-small cell lung cancer (NSCLC) cells are clinically amenable to treatment with tyrosine kinase inhibitors (TKIs) resulting in prolonged survival and significant benefit compared to cytotoxic chemotherapy. The most frequent genomic alterations are observed...

Descripción completa

Detalles Bibliográficos
Autores principales: Rath, Barbara, Plangger, Adelina, Hamilton, Gerhard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: OAE Publishing Inc. 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9090586/
https://www.ncbi.nlm.nih.gov/pubmed/35582610
http://dx.doi.org/10.20517/cdr.2019.85

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9090586/
https://www.ncbi.nlm.nih.gov/pubmed/35582610
http://dx.doi.org/10.20517/cdr.2019.85

Ejemplares similares